Lyra Therapeutics Terminates CEO and CFO Amid SEC Filing
ByAinvest
Monday, Jan 12, 2026 10:21 am ET1min read
LYRA--
Lyra Therapeutics has terminated its CEO Maria Palasis and CFO Jason Cavalier, according to an SEC filing. The company is a clinical-stage biotech firm focused on developing treatments for chronic rhinosinusitis. Its investigational products, LYR-210 and LYR-220, are bioresorbable nasal implants designed to deliver six months of continuous drug therapy. LYR-210 is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220 is being evaluated in the BEACON Phase II clinical trial.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet